Patents and financed projects
Since its creation, Health in Code has participated in numerous research projects, both nationally and internationally.
Financial Projects
LIQUID BIOPSY
hdh
OncohematoDx
diseases
The
MEGAPIPELINE
The European.
Atheroclonal
The.
COVID-19
The project carried out by Imegen for the manufacture, validation and placing on the market of new PCR kits for the diagnosis of COVID-19, has received funding from the Ministry of Industry, Commerce and Tourism, within the manufacturing aid program of medical supplies and products considered emergency by the Government in relation to COVID-19.
Inn Medical
The
NeumoviralDx
The
OncoPanel-TMB Plus
The general objective of the project is the research and development of a new comprehensive tool for the management of patients who are candidates for immunotherapy treatment. For this, Imegen proposes the design and validation of a new panel, based on NGS technology, which will include all those predictive biomarkers of immunotherapy efficacy, as well as a set of genes that will allow the selection of the type of treatment in the event that the patient is not suitable for immunotherapy.
The project will be fully executed at the Imegen facilities at C / Catedrático Agustín Escardino 9, 46980, Paterna Valencia. With an execution period that begins on 09/1/2018, and ends on 04/31/2020.
The project has a budget of € 806,814, with CDTI and FEDER co-financing in the form of a € 0.00 credit of 75% of the budget, and a non-reimbursable tranche that amounts to 30% calculated on the financial coverage of the help.
Industrialización
Imegen has received an aid to improve next-generation DNA sequencing capabilities. This action has been co-financed by the Consellería D’Economía Sostenible, Sectors Productius Comerç i Treball with an amount of € 157,710 through the file INPYME / 2019/348.
Through this instrument, Imegen will add the NovaSeq ™ 6000 Sequencing System to its technology portfolio.
Pharmacogenetics in breast cancer
Recently INSTITUTO DE MEDICINA GENÓMICA, SL has carried out this project with file number IMIDTA / 2018/6 that has been supported by IVACE in its call for aid to SME R&D Projects (PIDI-CV) and has been Co-financed by IVACE and the European Regional Development Fund (ERDF), within the framework of the ERDF Operational Program of the Valencian Community 2014/2020. The main objective of the project consists of the research and development of a new kit for the detection of mutations in the genes involved in familial breast and ovarian cancer in order to improve the quality of life of patients who inherit mutations in the BRCA1 genes and BRCA2, associated with these cancers.
ONCOMARKER
Design and development of an oncological biomarker analysis platform to establish prognosis and response to treatment in advanced or metastatic colorectal cancer. The platform will be a complete solution adapted to the needs of genetic analysis laboratories and hospital centers.
SMART-MAP
Imegen participates in the project “Biomarkers for precision oncology as a diagnostic tool”. The objective of the OncoPRECISION project is the design, development and validation of a genomic platform aimed at providing personalized precision medicine in patients with lung cancer, colorectal cancer, melanoma and poor prognosis carcinomas.
Through the cooperation between various agents of the Valencian Innovation System, such as the biotechnology company Imegen, the Foundation for Research of the General University Hospital of Valencia and the Prince Felipe Research Center, the results of this project will involve the development of solutions joint to a strategic line within the Valencian Community, such as precision medicine.
The project has been funded by the Valencian Agency for Innovation with a budget of € 500,000 through the 2018 Strategic Cooperation Projects aid program.
Betelasfe
Imegen and Betelgeux participate in the project “Evaluation of the impact of cleaning and disinfection operations on the microbiota of food industries”. This project aims to implement metagenomic sequencing techniques when evaluating the impact of cleaning and disinfection processes on the microbiota of the food industries. The project has been financed by the IVACE with an amount of € 45,165.91 through the aid program R&D PROJECTS IN COOPERATION, call IMIDCA EMP16 R&D IN COOPERATION.
Colorectal OncokitDX
Design and development of an oncological biomarker analysis platform to establish prognosis and response to treatment in advanced or metastatic colorectal cancer. The platform will be a complete solution adapted to the needs of genetic analysis laboratories and hospital centers.
OncoPRECISION
Design and development of an oncological biomarker analysis platform to establish prognosis and response to treatment in advanced or metastatic colorectal cancer. The platform will be a complete solution adapted to the needs of genetic analysis laboratories and hospital centers.
Denamic
Imegen participates in the European project Denamic (Developmental Neurotoxicity Assessment of Mixtures In Children).
This project aims to develop sophisticated tools and methods to analyze, early, how the exposure of different neurotoxic compounds affects the health of European children.
Plan de Internacionalización 2016
The “Imegen Internationalization Plan 2016” project has been financed by IVACE for an amount of € 23,133 through the ITAPIN IT aid program. 16 INTERNATIONALIZATION PLANS PYME CV.
Certify – CV 2018
The project “Platform for the diagnosis and management of somatic and hereditary cancer” has been financed by IVACE for an amount of € 1,500 through the aid program CERTIFICACION DE R + D + I (CERTIFICA-CV) 2018.
Grants and Research Projects
During the last 10 years Health in Code has been funded with more than five grants from the Spanish Reseach Ministry and several other national institutions; as well as awarded with four different fellowships from entities such as the Spanish Cardiology Society.
At the international level, we have participated in the “Anderson-Fabry Cardiomyopathy European Survey (ACE)”, coordinated by The Heart Hospital (UK, 2008); and within the 7th European framework in the following proyects: INHERITANCE: “Integrated Heart Research In Translational genetics of dilated Cardiomyopathies in Europe”; and BESTAGEING: “Biomarker research Alliance for Diagnosing Heart disease in the Ageing European Population”(2013-2017).
In addition, we are currently involved in the proyect CARDIOBIOME (FEDER-INNTERCONNECTA 2015) aimed at “Design and development of a platform to study microbiome as a biomarker for personalized medicine”.
Patents
Health in Code has filed a patent application of a novel method for the characterization of copy number variants (CNVs) and other structural variants that may cause disease.
CNVs and structural variants are mutations that involve loss or gain of genetic material. These mutations are currently detected using techniques such as MLPA, CGH Arrays or SNP Arrays. However, the plain detection is not enough for a proper report of the mutation and makes it difficult to perform segregation studies in relatives.
Health in Code’s patent solves this problem with the development of a simple, economical and fast method that is able to identify the actual boundaries and, if it´s the case, the insertion points of CNVs and structural variants. This will be of great help for the application of genetics in medical practice.
Academic collaborations: UDC-INIBIC
Health in Code has been involved in several training programs associated with the Biomedical Research Institute of A Coruña (INIBIC) and the University of A Coruña (UDC) related to NGS.
In addition, we regulary hold workshops and seminars towards the update and specialization of cardiologists in the application of NGS to inherited CVD and sudden death prevention.
